Results 81 to 90 of about 571,282 (185)

The FGF/FGFR System in the Biology and Therapeutic Landscape of Pediatric CNS Tumors

Medicinal Research Reviews, EarlyView.
ABSTRACT Central nervous system (CNS) tumors are the most common solid malignancies in children, comprising a highly heterogeneous group of neoplasms defined by distinct molecular alterations and clinical behaviors. Advances in molecular genetics have underscored the relevance of specific signaling pathways in driving pediatric tumorigenesis, among ...
Serena Filiberti, Camilla Tavani, Elena Somenza, Nicolas Tassone, Antonio d'Amati, Marta Turati, Roberto Ronca   +6 more
wiley   +1 more source

Isocitrate Dehydrogenase-Wildtype Glioma Adapts Toward Mutant Phenotypes and Enhanced Therapy Sensitivity Under D-2-Hydroxyglutarate Exposure

Biomedicines
Background/Objectives: Isocitrate dehydrogenase (IDH) mutations are hallmark features in subsets of gliomas, producing the oncometabolite D-2-hydroxyglutarate (2HG).
Geraldine Rocha, Clara Francés-Gómez, Javier Megías, Lisandra Muñoz-Hidalgo, Pilar Casanova, Jose F. Haro-Estevez, Vicent Teruel-Martí, Daniel Monleón, Teresa San-Miguel   +8 more
doaj   +1 more source

Farmer Survey Question Library

<p>Developed by <a href="https://akvo.org/" target="_self">Akvo</a> for <a href="https://www.idhsustainabletrade.com/" target="_self">IDH</a>, this question library forms the basis of the standardized survey ...
Brouwer, Jildemarie, Baruffa, Oscar, Keijser, Charlotte, Miriti, Mercy Makena   +3 more
core   +1 more source

Interlaboratory performance testing on EPIC v2.0 CNS tumor profiling demonstrates high reproducibility of tumor classification but reveals the need for harmonized copy number variation reporting

Brain Pathology, EarlyView.
Using the Infinium MethylationEPIC v2.0 array and Heidelberg Brain Tumor Classifier v12.8, 24 international laboratories achieved highly reproducible CNS tumor classification (97.9% correct; median β‐correlation r = 0.99), while copy number variation interpretation showed substantial interlaboratory variability, highlighting the need for harmonized CNV
Katrin Mauch‐Mücke, Christin Siewert, Lora Dimitrova, Sandra Pohl, Brendan Osberg, Annika K. Wefers, Julia Lorenz, Tanja Rothhammer‐Hampl, Till Acker, Alonso Barrantes‐Freer, Jean Boutonnat, Bérengère Dadone‐Montaudié, Claire Delbridge, Wolfgang Dietmaier, Sebastian Dintner, Hildegard Dohmen, Matthias Dottermusch, Daniel Erny, Katrin B. M. Frauenknecht, Tobias Goschzik, Patrick N. Harter, Daniela Hirsch, Yanghao Hou, Theo F. J. Kraus, Maggie Lee, Friederike Liesche‐Starnecker, Anne Mc Leer, Linea Melchior, Michael Mittelbronn, Wolf C. Müller, Shalima S. Nair, Julia E. Neumann, Pitt Niehusmann, Nicole Pfarr, Torsten Pietsch, Marco Prinz, Markus Rechsteiner, Regina Reimann, Laveniya Satgunaseelan, Veronica Skarpeteig, Anne J. Skjulsvik, Karl Sotlar, Isabelle Vanden Bempt, Erik Vassella, Katharina J. Weber, Gabriel Wasinger, Andreas Waha, Karen Zwaenepoel, Felix Sahm, Markus J. Riemenschneider, David Capper   +50 more
wiley   +1 more source

Targeting distinct amino acid metabolic vulnerabilities in IDH-mutant and IDH-wildtype gliomas

Acta Neuropathologica Communications
Lower grade gliomas frequently harbor mutations in isocitrate dehydrogenase (IDH), which define biologically distinct tumor subtypes. Although IDH-mutant and IDH-wildtype gliomas share similar histological morphology, they display markedly different ...
Shigeo Ohba, Akiyoshi Hirayama, Takao Teranishi, Keisuke Hitachi, Hisateru Yamaguchi, Kazuhiro Murayama, Manabu Natsumeda, Kensuke Tateishi, Kunihiro Tsuchida, Hiroaki Wakimoto, Hideyuki Saya, Russell Pieper, Yuichi Hirose   +12 more
doaj   +1 more source

ALT phenotype assessment in IDH‐mutant astrocytoma supports biologic consequence of ATRX missense mutations

Brain Pathology, EarlyView.
A meaningful subset of IDH‐mutant astrocytoma harbors ATRX missense variants that retain ATRX IHC immunoreactivity yet exhibit functional ALT activation, supporting the biologic relevance of these missense mutations.
Oguzhan O. Kizilkaya, Kevin Y. Zhang, Mohamed Sherief, Debraj Mukherjee, Chetan Bettegowda, Matthias Holdhoff, Victoria Croog, Solmaz Sahebjam, David O. Kamson, Jordina Rincon‐Torroella, Karisa C. Schreck, Charles G. Eberhart, Alan Meeker, Calixto‐Hope G. Lucas   +13 more
wiley   +1 more source

Clinical evaluation of the CrossNN DNA methylation classifier for central nervous system tumors

Brain Pathology, EarlyView.
CrossNN demonstrated non‐inferiority to the Heidelberg CNS Tumor Methylation Classifier. A dual‐classifier approach increased the number of clinically informative classifications with correct tumor type assignment while maintaining a low rate of incorrect predictions.
Jonas Dahnoun, Léon C. van Kempen, Senada Koljenović, Ken Op de Beeck, Tomas Menovsky, Bart Feyen, Melek Ahmed, Anne Sieben, Karen Zwaenepoel   +8 more
wiley   +1 more source

Molecular Characteristics and Novel Progress in Precision Targeted Therapy of IDH-Mutant Gliomas

罕见病研究
Mutation of the isocitrate dehydrogenase (IDH) gene is a critical driver event in diffuse gliomas. By catalyzing the production of an abnormal metabolite, 2-hydroxyglutarate (2-HG), IDH mutation triggers a series of molecular alterations, including ...
SUN Yishuo, ZHANG Wei
doaj   +1 more source

Complement receptor C3aR marks heterogeneous tumor‐associated macrophage states associated with improved survival in IDH‐wildtype glioblastoma

Brain Pathology, EarlyView.
C3aR expression in IDH‐wildtype glioblastoma is predominantly associated with the myeloid/macrophage compartment and heterogeneous macrophage states. C3aR‐high tumors are enriched among MGMT promoter‐methylated tumors and show improved overall survival, although the prognostic association requires independent validation.
Marion Imara, Yosra Bedoui, Théotime Pignolet, Sebastien Freppel, Camille Brochard, Auguste Delattre, David Cappellen, Luc Bauchet, Mohamed Khettab, Franck Ah‐Pine   +9 more
wiley   +1 more source

ISG20 promotes local tumor immunity and contributes to poor survival in human glioma

OncoImmunology, 2019
Recent evidence has confirmed that a mutation of the isocitrate dehydrogenase (IDH) gene occurs early in gliomagenesis and contributes to suppressed immunity.
Mengqi Gao, Yi Lin, Xing Liu, Yiming Li, Chuanbao Zhang, Zheng Wang, Zhiliang Wang, Yulin Wang, Zongze Guo   +8 more
doaj   +1 more source